Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma 3Solid Tumors 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Sarcoma 1Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1Carcinoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 14Whole-Body Irradiation 8Mycophenolic Acid 8Peripheral Blood Stem Cell Transplantation 7Cyclosporine 6Cyclophosphamide 6Cytarabine 5Azacitidine 4Thiotepa 3Tacrolimus 3Filgrastim 3Antilymphocyte Serum 3tipifarnib 2laromustine 2aldesleukin 2Methylprednisolone 2Etoposide 2Cyclosporins 2Cord Blood Stem Cell Transplantation 2Bortezomib 2Biopsy 24-phenylbutyric acid 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2venetoclax 1sargramostim 1lintuzumab 1itacitinib 1ispinesib 1ilorasertib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anemia, Refractory, with Excess of Blasts × darinaparsin × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡